title: [Oral anticoagulation in chronic kidney disease with atrial fibrillation].
abstract: Atrial fibrillation is a common finding in patients with chronic kidney disease (CKD), which increases markedly the embolism risk. The CHADS2 and HAS-BLED scales, used in the general population to assess the risk/benefit of oral anticoagulation (OAC), underestimate respectively the risk of embolism and haemorrhage in CKD, making it difficult to decide whether to use OAC or not. Based on the available evidence, it seems indicated to use OAC in stage 3 CKD, while it is controversial in advanced stages. New OAC such as dabigatran and rivaroxaban have been approved in stage 3 CKD but their role is still somewhat uncertain.
authors.affiliation: Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Cantabria, España.
authors.forename: Víctor
authors.initials: V
authors.lastname: Expósito
authors.affiliation: Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Cantabria, España.
authors.forename: Miguel
authors.initials: M
authors.lastname: Seras
authors.affiliation: Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Cantabria, España. Electronic address: nefffg@humv.es.
authors.forename: Gema
authors.initials: G
authors.lastname: Fernández-Fresnedo
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D000069604:Dabigatran / Q000627:therapeutic use; D004617:Embolism / Q000209:etiology / Q000517:prevention & control*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D018570:Risk Assessment; D012307:Risk Factors; D000069552:Rivaroxaban / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: Anticoagulación oral; Atrial fibrillation; Chronic kidney disease; Enfermedad renal crónica; Fibrilación auricular; Haemodialysis; Hemodiálisis; Ictus; Oral anticoagulation; Stroke